Automated synthesis of [18F]Florbetaben as Alzheimer's disease imaging agent based on a synthesis module system

Applied Radiation and Isotopes

Volumn 71, Issue 1, 2013, Pages 41-46

  Wang, Hongliang ^a,b   Guo, Xinyan ^b   Jiang, Shende ^b   Tang, Ganghua ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b TIANJIN UNIVERSITY   (China)

Author keywords

18F labeling; 18F Florbetaben; Automated synthesis

Indexed keywords

18F-LABELING; [18F]FLORBETABEN; ALZHEIMER'S DISEASE; AUTOMATED SYNTHESIS; CLINICAL TRIAL; ETHYL ESTERS; IMAGING AGENT; IN-PHASE; IN-VIVO; METHANE SULFONIC ACID; MODULE SYSTEMS; NUCLEOPHILIC FLUORINATION; RADIOCHEMICAL PURITY; RADIOLABELED IMAGING; RADIOSYNTHESIS; TOTAL SYNTHESIS;

FLUORINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

AUTOMATION;

FLORBETABEN; 4 (N METHYLAMINO) 4' (2 (2 (2 FLUOROETHOXY)ETHOXY)ETHOXY)STILBENE; 4-(N-METHYLAMINO)-4'-(2-(2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)STILBENE; ANILINE DERIVATIVE; FLUORINE; STILBENE DERIVATIVE;

ARTICLE; AUTOMATION; DRUG PURITY; DRUG SYNTHESIS; FLUORINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; PROCESS DEVELOPMENT; SEPARATION TECHNIQUE; ALZHEIMER DISEASE; CHEMISTRY; HUMAN; QUALITY CONTROL; SCINTISCANNING; SYNTHESIS;

ALZHEIMER DISEASE; ANILINE COMPOUNDS; AUTOMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FLUORINE RADIOISOTOPES; HUMANS; QUALITY CONTROL; STILBENES;

EID: 84867413445     PISSN: 09698043     EISSN: 18729800     Source Type: Journal    
DOI: 10.1016/j.apradiso.2012.09.014     Document Type: Article

References (17)

1. Barthel H., Sabri O. Florbetaben to trace amyloid-Β in the Alzheimer brain by means of PET. J. Alzheimers. Dis. 2011, 26:117-121.
2. 18F-AV-45: a PET agent for Abeta plaques in the brain. J. Nucl. Med. 2009, 50:1887-1894.
3. Förstl H., Kurz A. Clinical features of Alzheimer's disease. Eur. Arch. Psychiatry Clin. Neurosci. 1999, 249:288-290.
4. Heininger K. A unifying hypothesis of Alzheimers disease. IV. Causation and sequence of events. Rev. Neurosci. 2000, 11:213-328.
5. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
6. Johnson K.A., Jones K., Holman B.L., Becker J.A., Spiers P.A., Satlin A., Albert M.S. Preclinical prediction of Alzheimer's disease using SPECT. Neurology 1998, 50:1563-1571.
7. Klunk W.E., Engler H., Nordberg A., Wang Y.M., Blomqvist G., Holt D.P., Bergström M., Savitcheva I., Huang G.F., Estrada S., Ausén B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Lågström B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004, 55:306-319.
8. 18F-GE067: a radioligand for in vivo brain amyloid imaging. J. Nucl. Med. 2009, 50:818-822.
9. Lopez O.L., Smith G., Becker J.T., Meltzer C.C., Dekosky S.T. The psychotic phenomenon in probable Alzheimer's disease: a positron emission tomography study. J. Neuropsychiatry Clin. Neurosci. 2001, 13:50-55.
10. 18F-BAY94-9172. J. Nucl. Med. 2009, 50:309-315.
11. 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008, 7:129-135.
12. 11C]palmitate using a modified GE Tracerlab FXC-Pro. Appl. Radiat. Isot. 2011, 69:691-698.
13. Shoghi-Jadid K., Small G.W., Agdeppa E.D., Kepe V., Ercoli L.M., Siddarth P., Read S., Satyamurthy N., Petric A., Huang S.C., Barrio J.R. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am. J. Geriatr. Psychiatry 2002, 10:24-35.
14. 18F]-labeled imaging agents. Nucl. Technol. 2008, 31:846-849.
15. 11C]SB-13 PET. Am. J. Geriatr. Psychiatry 2004, 12:584-585.
16. 18F]BAY94-9172 with a new precursor. Nucl. Med. Biol. 2011, 38:121-127.
17. Zhang W., Oya S., Kung M.P., Hou C., Maier D.L., Kung H.F. F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting AΒ aggregates in the brain. Nucl. Med. Biol. 2005, 32:799-809.